Placental stem cell populations

• US 8,057,788 B2
• Filed: 12/28/2006
• Issued: 11/15/2011
• Est. Priority Date: 12/06/2000
• Status: Expired due to Term

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Hariri, Robert J.
• Primary Examiner(s): LI, QIAN JANICE
• Application Number:
  US11/648,813
• Publication Number:
  US 20070275362A1
• Time in Patent Office: 1,783 Days
• Field of Search: None
• US Class Current: 424/93.1
• CPC Class Codes: A61K 2035/122 for inducing tolerance or supression of immune responses
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/644 Beeswax; Propolis; Royal jelly; Honey
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/36 Lipids
• CPC Class Codes: C12N 2500/42 Organic phosphate, e.g. beta glycerophosphate
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2533/52 Fibronectin; Laminin
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0607 : Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.

Claims

1. Isolated human placental stem cells that are CD34⁻

, CD10⁺ and SH2⁺ as detected by flow cytometry, wherein said cells can be expanded.

2. The isolated human cells of claim 1, wherein the cells are HLA-DR⁻

.

3. The isolated human cells of claim 1, wherein said cells have the potential to differentiate into cells having one or more characteristics of osteogenic cells or chondrogenic cells.

4. The isolated human cells of claim 1, wherein said cells have been expanded.

5. The isolated human cells of claim 1 that are CD90⁺ or CD45⁻

, as detected by flow cytometry.

6. The isolated human cells of claim 1 that are CD90⁺ and CD45⁻

, as detected by flow cytometry.

7. The isolated human cells of claim 5 that are one or more of CD29⁺, CD38⁻

, CD44⁺, CD54⁺, SH3⁺ or SH4⁺, as detected by flow cytometry.

8. The isolated human cells of claim 6 that are one or more of CD29⁺, CD38⁻

, CD44⁺, CD54⁺, SH3⁺ or SH4⁺, as detected by flow cytometry.

9. The isolated human cells of claim 5 that are CD44⁺, as detected by flow cytometry.

10. The isolated human cells of claim 6 that are CD44⁺, as detected by flow cytometry.

11. The isolated human cells of claim 3, wherein said characteristics of osteogenic cells are at least one of cuboidal appearance, exhibition of mineralization, or expression of mRNA for alkaline phosphatase or osteopontin as assessed by RT-PCR.

12. The isolated human cells of claim 3, wherein said characteristics of chondrogenic cells are at least one of production of glycosaminoglycans, production of type II collagen, production of cartilage matrix acid mucopolysaccharides, or production of mRNA for type II collagen or type IX collagen as determined by RT-PCR.

13. The isolated human cell of claim 1, wherein said cells have the potential to differentiate into cells having characteristics of neurons or adipocytes.

14. The isolated human cells of claim 13, wherein said characteristics of neurons are at least one of expression of mRNA for nerve growth factor receptor or neurofilament heavy chain as determined by RT-PCR.

15. The isolated human cell of claim 13, wherein said characteristics of adipocytes are at least one of production of oil droplet vacuoles that stain with Oil Red, or expression of mRNA for lipase, fatty acid binding protein, PPAR-γ

2, lipoprotein lipase or osteopontin as determined by RT-PCR.

16. The isolated human cells of claim 1 that are tissue culture plastic adherent.

17. An isolated population of cells enriched for the cells of claim 1.

18. An isolated population of cells enriched for the cells of claim 2.

19. An isolated population of cells enriched for the cells of claim 5.

20. An isolated population of cells enriched for the cells of claim 6.

21. An isolated population of cells enriched for the cells of claim 7.

22. An isolated population of cells enriched for the cells of claim 8.

23. An isolated population of cells enriched for the cells of claim 9.

24. An isolated population of cells enriched for the cells of claim 10.